このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

CK Life Sciences Int'l. (Holdings) 将来の成長

Future 基準チェック /06

現在、 CK Life Sciences Int'l. (Holdings)の成長と収益を予測するのに十分なアナリストの調査がありません。

主要情報

n/a

収益成長率

n/a

EPS成長率

Biotechs 収益成長	34.9%
収益成長率	n/a
将来の株主資本利益率	n/a
アナリストカバレッジ	None
最終更新日	n/a

今後の成長に関する最新情報

更新なし

Recent updates

There's No Escaping CK Life Sciences Int'l., (Holdings) Inc.'s (HKG:775) Muted Revenues Despite A 32% Share Price Rise

May 03

CK Life Sciences Int'l. (Holdings)'s (HKG:775) Anemic Earnings Might Be Worse Than You Think

Apr 25

CK Life Sciences Int'l. (Holdings) (HKG:775) Use Of Debt Could Be Considered Risky

Mar 26

Here's Why CK Life Sciences Int'l. (Holdings) (HKG:775) Can Manage Its Debt Responsibly

Sep 27

Does CK Life Sciences Int'l. (Holdings) (HKG:775) Have A Healthy Balance Sheet?

Sep 16

Estimating The Intrinsic Value Of CK Life Sciences Int'l., (Holdings) Inc. (HKG:775)

Aug 21

These 4 Measures Indicate That CK Life Sciences Int'l. (Holdings) (HKG:775) Is Using Debt Extensively

Apr 14

CK Life Sciences Int'l., (Holdings) Inc. (HKG:775) Delivered A Weaker ROE Than Its Industry

Mar 18

If You Had Bought CK Life Sciences Int'l. (Holdings) (HKG:775) Shares Five Years Ago You'd Have Earned 45% Returns

Feb 01

What Kind Of Shareholders Hold The Majority In CK Life Sciences Int'l., (Holdings) Inc.'s (HKG:775) Shares?

Jan 04

CK Life Sciences Int'l. (Holdings) (HKG:775) Has A Somewhat Strained Balance Sheet

Dec 09

We Wouldn't Rely On CK Life Sciences Int'l. (Holdings)'s (HKG:775) Statutory Earnings As A Guide

Nov 18

このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、CK Life Sciences Int'l. (Holdings) は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。

シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。

業績と収益の成長予測

SEHK:775 - アナリストの将来予測と過去の財務データ ( )HKD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2023	5,323	17	353	514	N/A
9/30/2023	5,318	61	191	372	N/A
6/30/2023	5,314	104	29	230	N/A
3/31/2023	5,295	118	102	297	N/A
12/31/2022	5,276	132	175	364	N/A
9/30/2022	5,290	130	302	486	N/A
6/30/2022	5,305	128	430	608	N/A
3/31/2022	5,353	145	318	516	N/A
12/31/2021	5,402	163	206	424	N/A
9/30/2021	5,302	150	107	429	N/A
6/30/2021	5,201	138	7	435	N/A
3/31/2021	5,072	132	79	483	N/A
12/31/2020	4,943	125	151	531	N/A
9/30/2020	4,846	112	139	433	N/A
6/30/2020	4,750	98	128	335	N/A
3/31/2020	4,859	140	155	357	N/A
12/31/2019	4,967	182	181	379	N/A
9/30/2019	5,128	223	90	337	N/A
6/30/2019	5,288	263	-1	295	N/A
3/31/2019	5,261	263	-29	263	N/A
12/31/2018	5,233	263	-57	231	N/A
9/30/2018	5,077	261	N/A	N/A	N/A
6/30/2018	4,920	259	165	237	N/A
3/31/2018	4,807	259	102	186	N/A
12/31/2017	4,693	258	40	135	N/A
9/30/2017	4,674	247	N/A	N/A	N/A
6/30/2017	4,655	236	N/A	352	N/A
3/31/2017	4,762	244	N/A	396	N/A
12/31/2016	4,869	253	N/A	439	N/A
9/30/2016	4,933	240	N/A	N/A	N/A
6/30/2016	4,998	228	N/A	314	N/A
3/31/2016	4,959	223	N/A	309	N/A
12/31/2015	4,919	219	N/A	304	N/A
9/30/2015	4,953	257	N/A	N/A	N/A
6/30/2015	4,987	296	N/A	263	N/A
3/31/2015	4,970	280	N/A	294	N/A
12/31/2014	4,954	264	N/A	325	N/A
9/30/2014	4,930	250	N/A	312	N/A
6/30/2014	4,907	236	N/A	300	N/A
3/31/2014	4,939	232	N/A	283	N/A
12/31/2013	4,971	229	N/A	267	N/A
9/30/2013	4,851	215	N/A	291	N/A
6/30/2013	4,730	201	N/A	314	N/A

アナリストによる今後の成長予測

収入対貯蓄率: 775の予測収益成長が貯蓄率 ( 2.2% ) を上回っているかどうかを判断するにはデータが不十分です。

収益対市場: 775の収益がHong Kong市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です

高成長収益: 775の収益が今後 3 年間で大幅に増加すると予想されるかどうかを判断するにはデータが不十分です。

収益対市場: 775の収益がHong Kong市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。

高い収益成長: 775の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: 775の自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

CK Life Sciences Int'l. (Holdings) 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

Recent updates

There's No Escaping CK Life Sciences Int'l., (Holdings) Inc.'s (HKG:775) Muted Revenues Despite A 32% Share Price Rise

CK Life Sciences Int'l. (Holdings)'s (HKG:775) Anemic Earnings Might Be Worse Than You Think

Full year 2023 earnings released: EPS: HK$0.002 (vs HK$0.014 in FY 2022)

CK Life Sciences Int'l. (Holdings) (HKG:775) Use Of Debt Could Be Considered Risky

CK Life Sciences Int'l., (Holdings) Inc., Annual General Meeting, May 23, 2024

Full year 2023 earnings released: EPS: HK$0.002 (vs HK$0.014 in FY 2022)

New minor risk - Financial data availability

CK Life Sciences Int'l., (Holdings) Inc. to Report Fiscal Year 2023 Results on Mar 19, 2024

Ck Life Sciences Int'l., (Holdings) Inc. Announces Preclinical Data for Its Investigational Dual-Antigen Cancer Vaccines, Co-Targeting Prame and PD-L1

First half 2023 earnings released: EPS: HK$0.004 (vs HK$0.007 in 1H 2022)

Now 21% undervalued

Full year 2022 earnings released: EPS: HK$0.014 (vs HK$0.017 in FY 2021)

Less than half of directors are independent

Here's Why CK Life Sciences Int'l. (Holdings) (HKG:775) Can Manage Its Debt Responsibly

CK Life Sciences Int'l., (Holdings) Inc. Announces Retirement of Independent Non-Executive Director and Change in Composition of the Remuneration Committee

First half 2022 earnings released

CK Life Sciences Int'l., (Holdings) Inc. to Report First Half, 2022 Results on Aug 02, 2022

Investor sentiment improved over the past week

Upcoming dividend of HK$0.01 per share

Less than half of directors are independent

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

CK Life Sciences Int'l., (Holdings) Inc. to Report Fiscal Year 2021 Results on Mar 15, 2022

Now 20% undervalued after recent price drop

Does CK Life Sciences Int'l. (Holdings) (HKG:775) Have A Healthy Balance Sheet?

First half 2021 earnings released: EPS HK$0.01 (vs HK$0.009 in 1H 2020)

Estimating The Intrinsic Value Of CK Life Sciences Int'l., (Holdings) Inc. (HKG:775)

Upcoming dividend of HK$0.01 per share

Full year 2020 earnings released: EPS HK$0.013 (vs HK$0.019 in FY 2019)

These 4 Measures Indicate That CK Life Sciences Int'l. (Holdings) (HKG:775) Is Using Debt Extensively

CK Life Sciences Int'l., (Holdings) Inc. (HKG:775) Delivered A Weaker ROE Than Its Industry

Full year 2020 earnings released: EPS HK$0.013 (vs HK$0.019 in FY 2019)

Ck Life Sciences Int'l., (Holdings) Inc. Recommends Final Dividend for the Year Ended 31 December 2020, Payable on May 31, 2021

CK Life Sciences Int'l., (Holdings) Inc. to Report Fiscal Year 2020 Results on Mar 16, 2021

If You Had Bought CK Life Sciences Int'l. (Holdings) (HKG:775) Shares Five Years Ago You'd Have Earned 45% Returns

What Kind Of Shareholders Hold The Majority In CK Life Sciences Int'l., (Holdings) Inc.'s (HKG:775) Shares?

CK Life Sciences Int'l. (Holdings) (HKG:775) Has A Somewhat Strained Balance Sheet

We Wouldn't Rely On CK Life Sciences Int'l. (Holdings)'s (HKG:775) Statutory Earnings As A Guide

New 90-day low: HK$0.86

CK Life Sciences Int'l., (Holdings) Inc. Announces Directors Changes

New 90-day low: HK$0.89

CK Life Sciences Int'l., (Holdings) Inc. Announces Executive Changes

First half earnings released

CK Life Sciences Int'l., (Holdings) Inc. to Report Q2, 2020 Results on Aug 04, 2020

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘